Both in Pharmaceuticals
Gyre Therapeutics vs Relmada Therapeutics
Over the past year GYRE returned −39.6% and RLMD returned +95.7%; their daily moves had a correlation of 0.19.
GYRE −39.6% RLMD +95.7%Growth of $1, one year, split-adjusted
| Metric | GYRE | RLMD |
|---|---|---|
| Price | $4.45 | $4.31 |
| Market cap | $471.3M | $459.2M |
| Today | +0.11% | +0.82% |
| 1 month | −37.2% | +31.3% |
| 6 months | −44.7% | −45.2% |
| Year to date | −37.0% | −10.9% |
| 1 year | −39.6% | +95.7% |
| Revenue growth (YoY) | −2.1% | — |
| Gross margin | 92.4% | — |
| Net margin | −40.1% | — |
| P/E (TTM) | — | — |
| Price / sales | 3.9× | — |
| Net cash | $74.8M | $217.7M |
| Dividend yield | — | — |
| Volatility (60d) | 88.3% | 59.9% |
| Short % of float | 11.5% | 14.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).